Showing results (601-610 of 624) with videos related to

Sort By:
Pageof 63
SLAS Discovery : Advancing Life Sciences R & D|March 29, 2021
A Method for Determining the Kinetics of Small-Molecule-Induced UbiquitinationEllen F Vieux, Roman V Agafonov, Lydia Emerson, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
Haematologica|June 28, 2000
Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)A Pession, R Rondelli, P Paolucci, et al.
The Journal of Biological Chemistry|August 22, 2003
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neuronsMatthew S Goldberg, Sheila M Fleming, James J Palacino, et al.
Bone Marrow Transplantation|April 20, 2004
Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantationA P Iori, R Cerretti, L De Felice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1Theresa A Proia, Maneesh Singh, Richard Woessner, et al.
Blood|August 1, 1997
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative GroupsF Mandelli, D Diverio, G Avvisati, et al.
Leukemia|February 19, 2013
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibF Efficace, M Baccarani, M Breccia, et al.
Leukemia|May 3, 2016
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapyL Cicconi, M Divona, C Ciardi, et al.
Molecular Cancer Therapeutics|March 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ InhibitionLarissa S Carnevalli, Molly A Taylor, Matthew King, et al.
Pageof 63